IP Library › Granted Patent US 9,636,368
Granted Patent B2
US 9,636,368 · App. 14/823,585 · Granted May 2, 2017

Strain of

Inventors: Siao-Jhen Chen (Tainan, TW); Yen-Lin Chen (Hsinchu, TW); Hsun-Yin Hsu (Hsinchu, TW); Shy-Yunn Wann (Hsinchu, TW); Mei-Huei Chen (Hsinchu, TW); Li-Wen Yu (Hsinchu, TW)
Assignee: Food Industry Research and Development Institute
A61K35/747A23L2/382A23L33/135C12N1/20C12N9/0093C12P1/04C12R1/225A23L2/52A61K9/0095A61K9/19C12N1/02C12N2500/72C12Y117/03002
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,636,368
App. No.
14/823,585
Granted
May 2, 2017
Kind
B2
Abstract

A method for inhibiting xanthine oxidase and for reducing uric acid levels using a composition obtained by culturing Lactobacillus rhamnosus in a medium. Also disclosed is a composition including a metabolite of Lactobacillus rhamnosus for reducing uric acid levels in a subject and a method for producing the composition.

Claims (10)

1. A method for reducing uric acid levels in a subject, the method comprising culturing Lactobacillus rhamnosus in a medium to form a composition and administering the composition to a subject in need thereof in an amount effective for reducing uric acid levels, wherein the Lactobacillus rhamnosus is removed from the composition prior to the administering step.

2. The method of claim 1 , wherein the Lactobacillus rhamnosus is Lactobacillus rhamnosus I21 deposited under Accession No. DSM 28876.

3. The method of claim 1 , wherein the subject suffers from gout or hyperuricemia.

4. The method of claim 1 , wherein the composition is administered orally, intramuscularly, intradermally, intravenously, subcutaneously, intraperitoneally, intranasally, or mucosally.

5. The method of claim 1 , wherein the medium is de Man-Rogosa-Sharpe (MRS) broth, milk, or a juice.

6. The method of claim 1 , further comprising lyophilizing the composition to form a powder.

7. A method for producing a composition for reducing uric acid levels in a subject, the method comprising inoculating a medium with Lactobacillus rhamnosus , culturing the Lactobacillus rhamnosus in the medium, removing the Lactobacillus rhamnosus from the medium to form a composition free of Lactobacillus rhamnosus , and lyophilizing the composition, wherein the Lactobacillus rhamnosus is Lactobacillus rhamnosus I21 deposited under Accession No. DSM 28876.

8. The method of claim 7 , wherein the culturing is carried out for 2 days at 37° C.

9. The method of claim 8 , wherein a culture density prior to the removing step is 1×10 9 cells/ml.

10. A method for producing a composition for reducing uric acid levels in a subject, the method comprising inoculating a medium with Lactobacillus rhamnosus , culturing the Lactobacillus rhamnosus in the medium, removing the Lactobacillus rhamnosus from the medium to form a composition free of Lactobacillus rhamnosus , and sterilizing the composition by pasteurization, irradiation, autoclave, or filtration, wherein the Lactobacillus rhamnosus is Lactobacillus rhamnosus I21 deposited under Accession No. DSM 28876.

Continuity (2)
Provisional Application 62040616 · Aug 22, 2014
Related Publication 20160051602A1 · Feb 25, 2016